Pharma shares drag markets; Lupin, Sun Pharma dip 4%
Pharma shares were among the top losers with Sun Pharma declining the most04-11-2016
04-11-2016
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
Sudhir V Valia has submitted the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 to BSE29-10-2016
Sun Pharma Announces US Launch of Authorized Generics for Benicar, Benicar HCT, Azor and Tribenzor
Sun Pharmaceutical Industries Ltd has informed BSE regarding a Press Release dated October 27, 2016, titled "Sun Pharma Announces US Launch of Authorized Generics for Benicar, Benicar HCT, Azor and Tribenzor".27-10-2016
Sun Pharma to Acquire Ocular Technologies
Sun Pharmaceutical Industries Ltd has informed BSE that the Company has entered into an agreement to acquire 100% equity stake of Ocular Technologies, Sari.In this regard, the Company has submitted a copy of a Press Release dated October 26, 2016 titled "Sun Pharma to Acquire Ocular Technologies".27-10-2016
Sun Pharma buys eye care specialist Ocular Tech for $40 million
Sun Pharma will also pay more contingent on meeting drug development and sales milestones26-10-2016
Sun Pharma to announce second quarter results on November 10, 2016
Sun Pharmaceutical Industries Ltd has informed BSE regarding a Press Release dated October 26, 2016 titled "Sun Pharma to announce second quarter results on November 10, 2016".26-10-2016
Change in Window Closure Date for trading by Designated Persons
With reference to the earlier letter dated October 24, 2016, regarding the intimation of board meeting and window closure, Sun Pharmaceutical Industries Ltd has now informed BSE that the window closure for trading by designated persons as per Insider Trading Rules of the Company will be upto November 15, 2016, instead of November 14, 2016, due to November 14, 2016, being a stock exchange trading holiday....25-10-2016
Q2 results on Nov 10, 2016
Sun Pharmaceutical Industries Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on November 10, 2016, inter alia, to transact the following business:1. To consider and take on record the Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2016 (Q2).2. To consider the proposal for the merger/amalgamation of Ranbaxy Drugs Limited, Vidyut Investments Limited,...24-10-2016
Sun Pharma to set up R&D unit in M.P.
Sun Pharma has significant investment plans for its facility in Madhya Pradesh, the firm's Managing Director Dilip Shanghvi said. We have significant additional investments plans for our Madhya...23-10-2016
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
Jayant S Sanghvi has submitted the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 to BSE21-10-2016